GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Micromet, Inc. (MITI) [hlAlert]

Rating:
Outperform
MITI
up 86.27 %

Micromet, Inc. (MITI) rated Outperform with price target $8 by MP Advisors

Posted on: Wednesday,  Apr 6, 2011  10:25 AM ET by MP Advisors

MP Advisors rated Outperform Micromet, Inc. (NASDAQ: MITI) on 04/06/2011, when the stock price was $5.90. Since
then, Micromet, Inc. has gained 86.27% as of 03/07/2012's recent price of $10.99.
If you would have followed this MP Advisors's recommendation on MITI, you would have gained 86.27% of your investment in 336 days.

Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company?s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin?s lymphoma (NHL). A second BiTE antibody, MT110, is being tested in a phase I clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule (EpCAM), which is over-expressed in many solid tumors.

MP Advisors helped investors navigate the dynamic BioPharma industry for decades. Our flagship BioPharmaceutical Outlook™ maps the highs and lows of the year, assessing the critical success factors that can shape the industry's future.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/6/2011 10:25 AM Buy
None
5.90 8.00
as of 12/30/2011
1 Week down  -0.69 %
1 Month up  17.29 %
3 Months up  49.79 %
1 YTD up  21.86 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy